Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure

European Heart Journal

Volumn 19, Issue 5, 1998, Pages 753-760

  Van Veldhuisen, D J ^a   Boomsma, F ^b   De Kam, P J ^a   Man In't Veld, A J ^b   Crijns, H J G M ^a   Hampton, J R ^c   Lie, K I ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Ageing; Heart failure; Prognosis and neurohormones

Indexed keywords

ADRENALIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ENDOTHELIN; NEUROHORMONE; NORADRENALIN; RENIN;

ADRENALIN BLOOD LEVEL; ADULT; AGE; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NORADRENALIN BLOOD LEVEL; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIGOXIN; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; SURVIVAL RATE;

EID: 0032080728     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0840     Document Type: Article

References (30)

1. [1] Cowie MR, Mosterd A, Wood DA et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-25.
2. [2] Wei JY. Age and the cardiovascular system. N Engl J Med 1992; 327: 1735-9.
3. [3] Lakatta EG. Deficient neuroendocrine regulation of the cardiovascular system with advancing age in healthy humans. Circulation 1993; 87: 631-6.
4. [4] Dutka DP, Olivotto I, Ward S et al. Plasma neuro-endocrine activity in very elderly subjects and patients with and without heart failure. Eur Heart J 1995; 16: 1223-30.
5. [5] Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-54.
6. [6] Benedict CR, Johnstone DE, Weiner DH et al. for the SOLVD Investigators. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunction. J Am Coll Cardiol 1994; 23: 1410-20.
7. [7] Cody RJ, Torre S, Clark M, Pondolfino K. Age-related hemodynamic, renal, and hormonal differences among patients with congestive heart failure. Arch Intern Med 1989; 149: 1023-8.
8. [8] Wallén T, Landahl S, Hedner T, Hedner J, Hall C. Atrial peptides, ANP (1-98) and ANP (99-126) in health and disease in an elderly population. Eur Heart J 1993; 14: 1508-13.
9. [9] Hughes CV, Wong M, Johnson G, Cohn JN, for the V-HeFT VA Cooperative Studies Group. Influence of age on mechanisms and prognosis of heart failure. Circulation 1993; 87 (Suppl VI): VI-111-7.
10. [10] Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301-6.
11. [11] Bourassa MG, Gurné O, Bangdiwala SI et al. for the SOLVD Investigators. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993; 22 (Suppl A): 14A-9A.
12. [12] Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
13. [13] Lerman A, Gibbons RJ, Rodeheffer RJ et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-9.
14. [14] Hall C, Rouleau JL, Moyé L et al. N-terminal proatrial factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89: 1934-42.
15. [15] Pousset F, Isnard R, Lechat P et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997; 18: 254-8.
16. [16] DeBold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94.
17. [17] Yandle TG, Richards AM, Nicholls MG, Cueno R, Espiner EA, Livesay JH. Metabolic clearance rate and plasma half life of alfa-human atrial natriuretic peptide in man. Life Sci 1986; 38: 1827-33.
18. [18] Yanagisawa M, Kurihara H, Kimura K et al. A novel potent vasoconstricting peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
19. [19] Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-2.
20. [20] Hampton JR, van Veldhuisen DJ, Kleber FX et al. For the Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME-II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997; 349: 971-7.
21. [21] Boomsma F, Alberts G, Van Der Hoorn FAJ, Man in't Veld AJ, Schalekamp MADH. Simultaneous determination of free catecholamines and epinine and estimation of total epinine and dopamine in plasma and urine by high-performance liquid chromatography with fluorimetric detection. J Chromatogr 1992; 574: 109-17.
22. [22] Derkx FHM, Tan-Tjong L, Wenting GJ, Boomsma F, Man in't Veld AJ, Schalekamp MADH. Asynchronous change in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension 1983; 5: 244-56.
23. [23] van Veldhuisen DJ, Man in't Veld AJ, Dunselman PHJM et al. Double-blind, placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: Results of The Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993; 22: 1564-73.
24. [24] Bhaggoe UM, Boomsma F, Admiraal PJJ, Man in't Veld AJ, Schalekamp MADH. Stability of human plasma atrial natriuretic peptide during storage at - 80°C. Clin Chim Acta 1993; 223: 179-84.
25. [25] Florijn KW, Derkx FHM, Visser W et al. Plasma immunoreactive endothelin-1 in pregnant women with and without pre-eclampsia. J Cardiovasc Pharmacol 1991; 17 (Suppl 7): S446-8.
26. [26] Boomsma F, Bhaggoe UM, Man in't Veld AJ, Schalekamp MADH. Comparison of N-terminal pro-atrial natriuretic peptide and atrial natriuretic peptide in human plasma measured with commercially available radioimmunoassay kits. Clin Chim Acta 1996; 252: 41-9.
27. [27] Yu CM, Sanderson JE, Shum IOL et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Eur Heart J 1996; 17: 1694-702.
28. [28] Azizi C, Maistre G, Kalotka H et al. Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. J Endocrinol 1996; 148: 51-7.
29. [29] Cleland JGF, Ward S, Dutka D, Habib F, Impallomeni M, Morton IJ. Stability of plasma concentrations of N and C terminal atrial natriuretic peptides at room temperature. Heart 1996; 75: 410-3.
30. [30] Münzel T, Kurz S, Holtz J et al. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 1992; 86: 1089-98. European Heart Journal (1998) 19, 782-789